The Clinical Shift Toward Rapid-Acting Antidepressants
A new clinical overview published in Psychiatric Times on April 15, 2026 examines how prescribers are navigating treatment-resistant depression (TRD) — a condition affecting roughly 30% of people diagnosed with major depressive disorder who fail to respond to two or more adequate antidepressant trials. The piece spotlights esketamine (Spravato), the FDA-approved nasal spray formulation of ketamine's S-enantiomer, as a leading option for patients with TRD and acute suicidal ideation, while also exploring the broader landscape of glutamatergic interventions and the real-world barriers patients face in accessing them.
For anyone tracking ketamine therapy in any of its forms — infusions, troches, or oral tablets — this report offers meaningful insight into where clinical consensus is heading and what it signals for the future of at-home and outpatient ketamine access.
What the Report Actually Says
The Psychiatric Times overview emphasizes that clinician decision-making in TRD care is increasingly shaped by three factors: the urgency of symptom severity (particularly suicidal ideation), patient preference for treatment setting, and the logistical realities of access. Esketamine earns particular attention for its rapid onset — meaningful antidepressant effects can emerge within hours to days rather than the weeks typically required by SSRIs or SNRIs.
The mechanism is central to this speed advantage. Unlike conventional antidepressants that modulate serotonin or norepinephrine, esketamine — like all ketamine compounds — works primarily on the NMDA glutamate receptor system. This glutamatergic action triggers downstream neuroplasticity cascades, including BDNF release and synaptogenesis, which help explain why ketamine-class drugs can work when first- and second-line treatments have failed.
Importantly, the report also acknowledges the friction in the system. Esketamine requires in-office administration with a mandatory two-hour monitoring window after each dose. Insurance coverage remains inconsistent. And for patients in rural areas or with limited mobility, clinic-based infusion or nasal spray protocols create real access gaps — gaps that have increasingly pushed both patients and clinicians toward exploring oral and sublingual formulations as complements or alternatives.
How Oral Ketamine Tablets Fit Into This Picture
For readers here, the most relevant question is: where do oral ketamine tablets sit relative to esketamine in the clinical hierarchy?
The honest answer is that they serve different populations and different clinical moments. Esketamine, as a controlled in-office intervention, is positioned for acute crisis — patients with active suicidal ideation who need rapid stabilization under direct clinical supervision. That's a high-acuity use case with appropriate guardrails.
Oral ketamine tablets, by contrast, are increasingly used in the maintenance and step-down phase of treatment — helping patients sustain gains made during infusion series or acute interventions, or providing accessible, lower-intensity treatment for individuals with TRD who don't meet the threshold for crisis-level care but still aren't responding to standard antidepressants.
The pharmacokinetics here matter. Oral ketamine has lower bioavailability than intranasal esketamine — typically in the 20–30% range due to first-pass hepatic metabolism, compared to roughly 40–50% for nasal absorption. This means oral dosing requires careful calibration. The onset is slower (typically 30–60 minutes), the peak is more gradual, and the dissociative effects are generally milder at therapeutic doses. For many patients, this actually makes oral tablets easier to tolerate, particularly for long-term maintenance use without the need for clinical supervision at every session.
Sublingual troches occupy a middle ground — better absorption than swallowed tablets (bypassing first-pass metabolism to a greater degree), faster onset, but more variable depending on how long the lozenge is held under the tongue and individual salivary factors. Tablets that are specifically formulated for oral dissolution versus those meant to be swallowed whole will behave differently, and patients should clarify with their prescriber exactly how their formulation is intended to be used.
Key Takeaway
Esketamine's clinical profile — fast-acting, glutamatergic, supervised — confirms ketamine's place in serious depression care. But its access limitations are real. Oral ketamine tablets are filling a growing gap as a maintenance-phase and lower-acuity option. If you're using oral ketamine as part of a TRD treatment plan, understanding the bioavailability differences between your formulation and clinic-based alternatives helps you have better conversations with your prescriber about dosing expectations and therapeutic goals.
Practical Takeaways for Oral Ketamine Users
Ask about your formulation's intended absorption route. Not all oral ketamine tablets are designed the same way. Some are meant to be swallowed; others are designed to dissolve sublingually. The difference has a direct impact on how quickly you'll feel effects and at what dose range your prescriber is likely to start.
Understand what phase of treatment you're in. The clinical literature increasingly distinguishes between acute stabilization (where esketamine or IV infusion may have the strongest evidence base) and maintenance treatment (where oral formulations are gaining traction). Knowing which phase applies to you helps set realistic expectations for response timelines.
Don't self-adjust doses based on infusion or esketamine protocols. Dosing used in IV ketamine infusions or esketamine programs doesn't translate directly to oral tablet dosing. Bioavailability differences are significant enough that dose comparisons across routes can be misleading — and potentially unsafe without clinical guidance.
Access barriers are a legitimate clinical conversation. If you're facing insurance, geography, or scheduling barriers to clinic-based care, this report reinforces that you're not alone — and that clinicians are actively looking for alternatives. Raising oral ketamine options explicitly with a knowledgeable prescriber is increasingly appropriate and evidence-informed.
For the full clinical overview, see the original article at Psychiatric Times.
Share